KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $333.0 million.

  • Gilead Sciences' Change in Receivables rose 30555.56% to $333.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $474.0 million, marking a year-over-year increase of 26515.68%. This contributed to the annual value of -$139.0 million for FY2024, which is 1146.5% up from last year.
  • Latest data reveals that Gilead Sciences reported Change in Receivables of $333.0 million as of Q3 2025, which was up 30555.56% from $292.0 million recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Change in Receivables ranged from a high of $612.0 million in Q3 2023 and a low of -$975.0 million during Q1 2021
  • For the 5-year period, Gilead Sciences' Change in Receivables averaged around $18.1 million, with its median value being $66.0 million (2024).
  • Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 35930.85% in 2021, then skyrocketed by 90689.66% in 2025.
  • Gilead Sciences' Change in Receivables (Quarter) stood at -$41.0 million in 2021, then skyrocketed by 785.37% to $281.0 million in 2022, then tumbled by 178.29% to -$220.0 million in 2023, then surged by 67.27% to -$72.0 million in 2024, then surged by 562.5% to $333.0 million in 2025.
  • Its Change in Receivables stands at $333.0 million for Q3 2025, versus $292.0 million for Q2 2025 and -$79.0 million for Q1 2025.